Growth, Growth Hormone Testing and Response to Growth Hormone Treatment in Gitelman Syndrome

A. Slyper
DOI: https://doi.org/10.1515/JPEM.2007.20.2.257
Abstract:This report describes a child who presented for an endocrine evaluation because of short stature, poor growth and inadequate weight gain, and was found to have growth hormone (GH) insufficiency. She had an excellent response to GH treatment. Only when a stress fracture was noted and further testing pursued was the diagnosis of Gitelman syndrome established. Gitelman syndrome is a genetic condition inherited in an autosomal recessive manner and characterized by hypokalemia and hypomagnesemia as a result of impaired renal conservation of potassium and magnesium. It is due to a defect in the distal convoluted tubule thiazide-sensitive NaC1 cotransporter. Inhibition of sodium chloride absorption leads to enhanced calcium reabsorption and hypocalciuria. Renal magnesium loss and hypomagnesemia also occur. The condition may be asymptomatic, although poor growth and weight gain are common features. Fatigue, chondrocalcinosis, and carpopedal spasms due to a further lowering of magnesium during episodes of vomiting or diarrhea have also been described'. Gitelman syndrome needs to be distinguished from Barrier's syndrome. Hypokalemia is present in both syndromes, but Barrier's syndrome is usually more severe and diagnosed at a younger age. Only about one-third of patients with Barrier's syndrome have hypomagnesemia. It is due to a number of genetic transporter abnormalities in the thick ascending limb of the loop of Henle. P A T I E N T R E P O R T
What problem does this paper attempt to address?